期刊文献+

HPLC测定甲磺酸加雷沙星异构体 被引量:2

Determination of Enantiomers in Garenoxacin Mesylate by HPLC
原文传递
导出
摘要 目的 建立甲磺酸加雷沙星异构体的HPLC检测方法。方法 Chiralpak AD-H色谱柱(250 mm×4.6 mm,5μm),柱温:35℃,检测波长:278 nm,流速:1.0 m L·min-1,流动相:正己烷-异丙醇-甲醇-甲磺酸(70∶29∶1∶0.1)。结果 甲雷沙星及其异构体在0.005~0.151μg·m L-1内具有良好的线性(r〉0.999),定量限浓度为5 ng·m L-1(相当于0.03%),最低检测限为2.5 ng·m L-1(相当于0.015%)。结论 该方法简便、准确,具有良好的重现性和专属性。 OBJECTIVE To establish an HPLC method for determining of enantiomers in garenoxacin mesylate. METHODS The column was Chiralpak AD-H(250 mm×4.6 mm, 5 μm) was used. Column temperature was 35 ℃, detection wavelength was 278 nm, flow rate was 1.0 m L·min-1, and the mobile phase consisted of n-hexane-isopropanol-methanol-methanesulfonic acid(70∶29∶1∶0.1). RESULTS The calibration curves of garenoxacin and enantiomers were linear over the range of 0.005-0.151 μg·m L-1(r0.999). The limit of quantification was 5 ng·m L-1(equivalent to 0.03%). The minimum detection limit was 2.5 ng·m L-1(equivalent to 0.015%). CONCLUTION The method is sample, accurate, reproducible and specific for determination of ethyl methanesulfonate in carenoxacin mesylate.
出处 《中国现代应用药学》 CAS CSCD 2015年第7期840-843,共4页 Chinese Journal of Modern Applied Pharmacy
关键词 甲磺酸加雷沙星 异构体 高效液相色谱法 garenoxacin mesylate enantiomers HPLC
  • 相关文献

参考文献3

二级参考文献13

  • 1袁佩,林蕾,范琦,曾令高.西他沙星差向异构体的毛细管电泳分离[J].色谱,2006,24(5):513-515. 被引量:7
  • 2GAJJAR DA, BELLO A, GE Z, et al. Multiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects [ J ]. Antirnicrob Agents Chemother, 2003, 47 (7) : 2256 - 2263.
  • 3TAKAHATA M, MITSUYAMA J, YAMASHIRO Y, et al. In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6 ) -quinolone [ J ]. Antimicrob Agents Chemother, 1999, 43(5) :1077 - 1084.
  • 4FUNG-TOMC JC, MINASSIAN B, KOLEK B, et al. Antibacterial spectrum of a novel des-fluoro (6) quinolone, BMS2284756 [J]. Antimicrob Agents Chemother, 2000, 44 (12): 3351 - 3356.
  • 5GORDON KA, PFALLER MA, JONES RN, et al. BMS284756 ( formerly T-23811, a des-fluoroquinolone) potency and spectrum tested against over 10000 bacterial bloodstream infection isolates from the SENTRY antimicrobial surveillance programme (2000) [J]. J Antimicrob Chemother, 2002, 49 (5): 851 -855.
  • 6ROLSTON KV, FRISBEE-HUME S, LEBLANC BM, et al. Antimicrobial activity of a noval des-fluoro (6) quinolone, garenoxacin( BMS284756), compared to other quinolones, against clinical isolates from cancer patients[ J ]. Diagn Microbiol Infect Dis, 2002, 44 (2) : 187 - 194.
  • 7LIEBETRAU A, RODLOFF AC, BEHRA-MIELLET J, et al. In vitro activities of a new des-fluoro (6) quioolone, garenoxacin, against clinical anaerobic bacteria [ J ]. Antimicrob Agents Chemother, 2003, 47 (11) : 3667 -3671.
  • 8PANKUCH GA, JACOBS MR, APPELBAUM PC. Postanibiotic effects of garenoxacin ( BMS2284756 ) against 12 gram-positive or negative organisma[ J]. Antimicrob Agents Chemother, 2003, 47 (3): 1140 -1142.
  • 9LOPEZ SJ, PROFANT M, KOSTRICA R, et al. Oral garenoxacin in the treatment of acute bacterial maxillary sinusitis: a Phase Ⅱ, multi-center, non-comparative, open-label study in adult patients undergoing sinus aspiration[J]. Clin Ther, 2007, 29(8): 1632 - 1644.
  • 10LOPEZ SJ. An open-label, multi-center, non-comparative study of oral BMS284756 in the treatment of acute bacterial sinusitis in patients undergoing sinus aspirate [ C ]//Annu Meet Infect Dis Soc Am, San Francisco: 2001 : 450.

共引文献10

同被引文献23

引证文献2

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部